CoChat

Agomelatine Improves Apathy in Frontotemporal Dementia

Callegari, Ilaria, Mattei, Chiara, Benassi, Francesca, Krueger, Frank, Grafman, Jordan, Yaldizli, Özgür, Sassos, Davide, Massucco, Davide, Scialò, Carlo, Nobili, Flavio, Serrati, Carlo, Amore, Mario, Cocito, Leonardo, Emberti Gialloreti, Leonardo, Pardini, Matteo · 2016 · Neurodegenerative Diseases
Cited by 54

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background/Aims: Apathy is the most common initial symptom of frontotemporal dementia (FTD) and has been linked to frontal-subcortical dopaminergic system dysfunction. No pharmacological therapy has been approved for the treatment of apathy, but, on the basis of its physiopathological mechanism, we suspected that increasing prefrontal dopaminergic innervation could improve this disabling symptom. Methods: We evaluated a group of 24 nondepressed patients with a diagnosis of the behavioral variant of FTD, in order to determine the effectiveness on apathy of agomelatine, an antidepressant with MT1 and MT2 receptor agonism and 5-HT2C receptor antagonism; the latter leads to an increase in prefrontal dopaminergic and noradrenergic tone. To try to tease out the effects of 5-HT2C antagonism on apathy, patients were randomized, using a cross-over design, to receive either agomelatine 50 mg/day or sustained release melatonin 10 mg/day for 10 weeks in a double-blind procedure. At the end of the follow-up period, subjects receiving melatonin switched to agomelatine for the following 10 weeks. Results: Agomelatine, but not melatonin, was associated with a significant reduction of apathy in FTD subjects and of caregiver distress due to patients' apathy. The switch from melatonin to agomelatine was associated with a reduction in apathetic behavior. Agomelatine was well-tolerated by all enrolled subjects. Conclusions: Our data, albeit preliminary, suggest that agomelatine could represent a novel useful approach to the treatment of apathy in FTD patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000445873

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 54

Metadata

Authors
Callegari, I., Mattei, C., Benassi, F., Krueger, F., Grafman, J., Yaldizli, Ö., Sassos, D., Massucco, D., Scialò, C., Nobili, F., Serrati, C., Amore, M., Cocito, L., Emberti Gialloreti, L., & Pardini, M.
Venue
Neurodegenerative Diseases
Publisher
S. Karger AG
Published
2016
Volume
16
Issue
5-6
Pages
352-356
ISSN
  • 1660-2854 (ISSN-L)
  • 1660-2862
OpenAlex
W2394522723
Cited by
54
References
3
FWCI
4.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Agomelatine Improves Apathy in Frontotemporal Dementia. https://app.cochat.ai/papers/10.1159/000445873
The paper
Callegari, I., Mattei, C., Benassi, F., Krueger, F., Grafman, J., Yaldizli, Ö., Sassos, D., Massucco, D., Scialò, C., Nobili, F., Serrati, C., Amore, M., Cocito, L., Emberti Gialloreti, L., & Pardini, M. (2016). Agomelatine Improves Apathy in Frontotemporal Dementia. Neurodegenerative Diseases. https://doi.org/10.1159/000445873

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.